Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a Phase 2 clinical trial titled A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC. The study aims to evaluate the safety and efficacy of combining fianlimab, cemiplimab, and chemotherapy compared to cemiplimab and chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC).
The trial tests the combination of fianlimab, an experimental drug, with cemiplimab and platinum-doublet chemotherapy. These drugs are administered intravenously every three weeks to assess their effectiveness as peri-operative therapy for NSCLC.
This interventional study is randomized with a parallel assignment and quadruple masking, focusing primarily on treatment. It seeks to determine the best combination for improving patient outcomes in early-stage NSCLC.
The study began on July 16, 2024, and the latest update was submitted on July 18, 2025. These dates are crucial for tracking the study’s progress and any emerging results.
The outcome of this study could significantly impact Regeneron’s stock performance and investor sentiment, especially if the combination proves more effective than current treatments. It could also influence the competitive landscape in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.